Home News

News

Astellas Pharma. Exhibition booth during the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

Astellas and Seagen Submit sBLA for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial...

Astellas Pharma and Seagen have confirmed that the companies have completed the submissions for two supplemental Biologics License Applications...

MSD and Starpharma Sign Research Agreement

Australia's Starpharma and Merck & Co have signed a Research Agreement allowing Merck to conduct a preclinical research evaluation...
Research associate at Genmab, Cell culturing. Photo courtesy: 2020 Genmab/Tuala Hjarnø and Torkil Stavdal

Biologics License Application for Tisotumab Vedotin Submitted to the U.S. Food and Drug Administration

Genmab and Seagen have submitted a Biologics Licence Application or BLA to the U.S. Food and Drug Administration (FDA)...

Enrollment Completed for Pivotal Phase II Clinical Trial of Camidanlumab Tesirine in Relapsed or...

Enrolment for the pivotal Phase II clinical trial (NCT04052997) evaluating the efficacy and safety of camidanlumab tesirine (formerly ADCT-301)...

HERTHENA-Lung01 Study of Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCLC

A first patient has been dosed in HERTHENA-Lung01, a phase II study evaluating patritumab deruxtecan, a HER3 directed DXd...

First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer

A first patient has been dosed in the dose-expansion cohort of the Phase I study with STRO-002, a folate...
Speakers and attendees during Global Capacity Building Showcase at the American Society of Hematology 61th Annual Meeting at the Orange County Convention Center on Sunday December 8, 2019. Photo Courtesy 2019 © ASH/Nick Agro

ASH 2020: Preclinical Models Identify CD74 as Potential Target for the Treatment of Acute...

Presentations during the virtual 62nd American Society of Hematology (ASH) Annual Meeting for the ongoing Phase 1 dose-escalation clinical...

ASH 2020: ECHELON-1 and ECHELON-2 and other Results with Brentuximab Vedotin

Presentations discussing brentuximab vedotin (Adcetris®; Seagen/Takeda) presented during the 62nd American Society of Hematology (ASH) Annual, Meeting, and Exposition,...

ASH 2020: Positive Interim Phase I Study Results of TRPH-222 in Patients with R/R...

TRPH-222 (CD22-4AP), an antibody-drug conjugate (ADC) being developed by Triphase, demonstrated early signs of efficacy with favorable tolerability at...

ASH 2020: Potential of Belantamab Mafodotin in Combination Standard Therapies in Treatment of Multiple...

Multiple myeloma is the second most common hematological malignancy in the United States and is generally considered treatable, but...